Medtronic Plc  (MDT)
Other Ticker:  
Price: $83.7300 $0.63 0.758%
Day's High: $83.35 Week Perf: 0.00
Day's Low: $ 82.61 30 Day Perf: -6.35 %
Volume (M): 893 52 Wk High: $ 95.60
Volume (M$): $ 74,293 52 Wk Avg: $84.74
Open: $83.14 52 Wk Low: $75.77

 Market Capitalization (Millions $) 111,528
 Shares Outstanding (Millions) 1,332
 Employees 95,000
 Revenues (TTM) (Millions $) 30,772
 Net Income (TTM) (Millions $) 4,088
 Cash Flow (TTM) (Millions $) 1,043
 Capital Exp. (TTM) (Millions $) 1,470

Medtronic Plc
Medtronic is a world leading medical technology company, providing lifelong solutions for people with chronic disease. We are committed to offering market-leading therapies worldwide to restore patients to fuller, healthier lives. With beginnings in the treatment of heart disease, we have expanded well beyond our historical core business and today provide a wide range of products and therapies that help solve many challenging, life-limiting medical conditions. We hold market-leading positions in almost all of the major markets in which we compete.

We currently function in five operating segments that manufacture and sell device-based medical therapies. Our operating segments are:

' Cardiac Rhythm Management (CRM)

' Spinal, Ear, Nose and Throat (ENT) and Surgical Navigation Technologies (SNT)

' Neurological and Diabetes

' Vascular

' Cardiac Surgery

Medtronic was founded in 1949, incorporated as a Minnesota corporation in 1957 and today serves physicians, clinicians and patients in more than 120 countries worldwide. Beginning with the development of the heart pacemaker in the 1950s, we have assembled a broad and diverse portfolio of progressive technology expertise both through internal development of core technologies as well as acquisitions. We remain committed to a mission written by our founder more than 40'years ago that directs us "to contribute to human welfare by application of biomedical engineering in the research, design, manufacture and sale of products that alleviate pain, restore health and extend life."

our success in leading global advances in medical technology is rooted in several key strengths:

' Broad and deep technological knowledge of microelectronics, implantable devices and techniques, power sources, coatings, materials, programmable devices and related areas, as well as a tradition of technological pioneering and breakthrough products that not only yield better medical outcomes, but more cost-effective therapies.

' Strong intellectual property portfolio that underlies our key products.

' High product quality standards, backed with stringent systems to ensure consistent performance, that meet or surpass customers expectations.

' Strong professional collaboration with customers, extensive medical educational programs and thorough clinical research.

' Full commitment to superior patient and customer service.

' Long experience with the regulatory process and sound working relationships with regulators and reimbursement agencies, including leadership roles in helping shape policy.

' A proven financial record of sustained growth and continual introduction of new products.

Customers and Competitors

The primary medical specialists who use our implanted cardiac rhythm devices include electrophysiologists, implanting cardiologists and cardiovascular surgeons. We hold the leading market position among implantable cardiac rhythm device manufacturers. Our primary competitors in this business are Guidant Corporation and St. Jude Medical,'Inc.

The primary medical specialists who use our spinal and SNT products are spine surgeons, orthopedic surgeons and neurosurgeons. The primary medical specialists who use our ENT products are ENT surgeons (otorhinolaryngologists). Our primary competitors in the Spinal business are Zimmer'Inc., Johnson'&'Johnson, Inc., Stryker Corporation, and Synthes-Stratec,'Inc.; the most significant competitors in the ENT business are Gyrus Group PLC and Stryker Corporation; and the primary competitors in the SNT business are BrainLAB,'Inc. and Stryker Corporation.

The primary medical specialists who use our neurological products are neurosurgeons, neurologists, pain management specialists, and orthopedic spine surgeons. The primary medical specialists who use our diabetes products are endocrinologists and internists, and those who use our gastroenterology and urology products are urologists, urogynecologists and gastroenterologists. Our primary competitors for neurological products are Advanced Neuromodulation Systems,'Inc., Johnson' & Johnson, Inc., Boston Scientific Corporation and Stryker Corporation. Our most significant competitors for diabetes products are Animas Corporation, Roche'Ltd. and Smiths Group plc. Our primary competitors for gastroenterology and urology products are Boston Scientific Corporation and Urologix,'Inc.

The primary medical specialists who use our products for treating coronary artery disease are interventional cardiologists, while products treating peripheral vascular disease may be used by interventional radiologists, vascular surgeons and interventional cardiologists. Our primary competitors in the Vascular business are Boston Scientific Corporation, Guidant Corporation and Johnson'& Johnson,' Inc.

The principal medical specialists who use our cardiac surgery products are cardiac surgeons. Our primary competitors in the Cardiac Surgery business are Edwards LifeSciences Corporation, Guidant Corporation, Johnson'& Johnson, Inc., and St. Jude Medical,'Inc.

   Company Address: 20 On Hatch, Lower Hatch Street Dublin 2 0
   Company Phone Number: 438-1700   Stock Exchange / Ticker: NYSE MDT
   MDT is expected to report next financial results on June 22, 2023.

Customers Net Income grew by MDT's Customers Net Profit Margin fell to

1.84 %

3.06 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
BDX   -0.12%    
BSX   -1.04%    
PDCO        1.92% 
SYK        0.84% 
ABT   -2.41%    
DHR        0.32% 
• View Complete Report

Vivos Therapeutics Inc

Deficit In spite of revenue growth at the company amid the fiscal first quarter of 2023

Investors in Vivos Therapeutics Inc received some mixed news during the first quarter of the 2023 earnings season. On the one hand, the company reported a net loss of $-0.07 per share, which was an improvement from the $-0.25 loss experienced a year ago. However, this also represented a decline from the previous quarter's $0.00 per share earnings.
Despite this mixed performance on the earnings front, the company experienced revenue growth of 5.845% when compared to the same quarter a year ago. During Q1 2023, Vivos Therapeutics Inc generated $3.86 million in revenue, up from $3.64 million a year ago. However, there was a sequential revenue decline of -2.354% from $3.95 million.

The Cooper Companies Inc

The Medical Equipment and Supplies company declared a single digit Top-line elevation, amid the fiscal second quarter of 2023

As a journalist, I have analyzed the financial results of The Cooper Companies Inc in the fiscal second quarter of 2023. The company's revenue managed to inch up by 5.736% to $877.40 million as compared to last year's $829.80 million. This suggests that the company has been able to generate more sales in the current period showcasing a positive trend. However, on the earnings per share front, things were not looking as good. The EPS dropped by -68.63% to $0.80 per share, from $2.55 in the previous quarter.
In comparison to the preceding period, revenue increased by 2.202%, but the profits plummeted drastically, with the EPS decreasing by -52.94% from $1.70. The company's bottom line of $39.800 million fell -68.56% from $126.600 million in the corresponding period a year earlier.

Ra Medical Systems Inc

Ra Medical Systems Inc has failed to turn into profitability despite of epic Surge in revenue in the January to March 31 2023 period

Ra Medical Systems Inc Achieves Strong Revenue Elevations in Q1 2023, But Reports Increased Loss Per Share
Ra Medical Systems Inc, a California-based medical device company that specializes in vascular and dermatology therapy, announced very strong revenue elevations of 844.444% year on year in the fiscal first quarter of 2023. The company's revenue for Q1 2023 was $0.09 million, a significant increase from its revenue of $0.01 million for the same period in 2022. Although the revenue increase is exciting news for Ra Medical, the company also reported an increase in its loss per share.
The loss per share for Q1 2023 was $-24.65, an alarming rise from the preceding quarter's loss per share of $-0.25 and from its previous net income of $0.00 million. The increase in loss per share can be attributed primarily to the company's recent investments in research and development and sales and marketing. These investments were necessary to boost product development and promote commercialization of Ra Medical's products.

Delcath Systems Inc

Delcath Systems Inc announced the deficit has been cut back remarkably, over the January to March 31 2023 period

Investors, get ready to rejoice! Delcath Systems Inc has delivered some impressive results for the first quarter of 2023. The company reported a whopping 57.937% revenue growth to $0.60 million, which has effectively helped to bring down losses to $-0.77 per share. This is a significant improvement from the $-1.00 per share loss reported in the same quarter last year.
Despite a decline in revenue in Q4, it's worth noting that the company managed to improve its EPS from $-0.88 to $-0.77 per share in the most recent quarter. It's always a good indication when a company is able to cut losses and improve profitability.

Haemonetics Corporation

Breathtaking financial reporting period by at the Haemonetics Corporation during the February to April 01 2023 span

Investors in Haemonetics Corporation can expect solid growth and increased earnings based on the company's fiscal fourth quarter 2023 financial results. The medical equipment and supplies company reported an impressive 71.13% increase in income per share to $0.77 compared to the previous year, while revenues grew by 31.706% to $342.13 million.
The company's net earnings also saw a healthy increase of 69.37% to $39.348 million. Although operating margin fell to 13.54%, the net margin actually improved to 11.5%. Operating earnings, however, only improved by 29.97% to $46.336 million.


Medtronic Plc's Segments
Cardiac Rhythm Management
 Segment     of total Revenue
 Segment     of total Revenue
Spinal & ENT
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Cardiac Vascular
 Segment     of total Revenue
Restorative Therapies
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Medtronic Plc announced annual revenue outlook on

Earnings Outlook
Medtronic Plc issued annual earnings guidance on

Geographic Revenue Dispersion
United States
Asia Pacific


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071